Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept & continue
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Slowdown ahead for UK housing market
    • China seeks more island security pacts to boost clout in Pacific
    • ‘Different from the US’: why Japan does not worry about inflation
    • Military briefing: Ukraine seeks way to break Russia’s Black Sea blockade
    • Gerhard Schröder steps down as Rosneft chair after Ukraine backlash
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Wall Street stocks flirt with bear market as growth concerns mount
    • Is the global economy heading for recession?
    • Why on earth did Warren Buffett swap Wells Fargo for Citigroup?
    • China seeks more island security pacts to boost clout in Pacific
    • Crypto lender Celsius Network stung by sell-off in digital asset market
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • Why on earth did Warren Buffett swap Wells Fargo for Citigroup?
    • HSBC banker draws fire after accusing policymakers of climate change hyperbole
    • Mercedes-Benz faces steep road to reach ‘luxury’ status
    • Tennis governing bodies strip Wimbledon of ranking points over Russia ban
    • Nationwide warns inflation surge will hit house prices
  • Tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    • Cryptocurrencies
    Most Read
    • Wall Street stocks flirt with bear market as growth concerns mount
    • Live news updates from May 20: Russia vows to expand military after Nato moves, S&P 500 sinks for seventh straight week
    • Investors spooked as gloom grips markets
    • What are investors supposed to trust in now?
    • The recession session II
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
    Most Read
    • Why on earth did Warren Buffett swap Wells Fargo for Citigroup?
    • Pessimism engulfs the Chinese economy as foreign investment fades
    • An abandoned subway is a tragedy for New York
    • Why Goldman staff should not bank on limitless holidays
    • Élisabeth Borne, a French technocrat with a political point to prove
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    Most Read
    • As a longtime trailing spouse, how do I get back into full-time work?
    • Are universities suffering from management bloat?
    • Spreadsheets are now cool, thanks to TikTok
    • Bonuses are outdated in the age of knowledge work
    • “Oleg, it’s obviously great news that you have not been sanctioned”
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • Ukraine’s ex-president Petro Poroshenko: ‘The army is like my child, and I am very proud’
    • Smart, co-operative, emotional: what cutting-edge science tells us about pigs
    • Are low-traffic neighbourhoods good for our cities?
    • Bridging loans surge as UK buyers scramble for property
    • The men who stick to a strict style diet
  • How to Spend It
MenuSearch
  • Home
  • World
  • US
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Work & Careers
  • Life & Arts
  • How to Spend It
Financial Times
SubscribeSign In

Your guide to a disrupted world

Start a 4-week trial

Hannah Kuchler

Global Pharmaceuticals Correspondent
Hannah Kuchler reports on the pharmaceutical industry and the Covid-19 pandemic. She previously covered US pharma and biotech in New York and the technology industry in Silicon Valley.
Email Hannah Kuchler @hannahkuchler  on Twitter (link opens in a new browser window)
Email Hannah Kuchler @hannahkuchler  on Twitter (link opens in a new browser window)

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Monday, 9 May, 2022
    Covid-19 vaccines
    BioNTech beats forecasts on back of Covid vaccine demand

    German biotech maintains guidance but prepares for fall in sales because of jab oversupply

  • Sunday, 1 May, 2022
    Coronavirus pandemic
    Bill Gates calls for global surveillance team to spot pandemic threats

    The philanthropist urges world leaders to increase spending to improve preparedness for health threats

  • Sunday, 1 May, 2022
    Coronavirus pandemic
    Africa’s top Covid vaccine plant faces uncertain future after production halted

    The problems threaten plans to produce 60 per cent of all vaccines administered in Africa locally by 2040

  • Sunday, 1 May, 2022
    CMR Surgical
    Robotic surgery group CMR urges more UK support for manufacturing

    Chief executive concerned country will become a less attractive place for skilled workers

  • Friday, 29 April, 2022
    AstraZeneca PLC
    AstraZeneca sales beat forecasts on Covid jab demand

    Revenue rises 60% as Alexion acquisition and its rare diseases medicines boost drugmaker’s earnings

  • Thursday, 28 April, 2022
    Drugs research
    Eli Lilly says obesity drug has similar results to weight-loss surgery

    Late-stage trial of Tirzepatide could be a ‘potential breakthrough’ in treatment, says US drugmaker

  • Wednesday, 27 April, 2022
    GlaxoSmithKline PLC
    GSK beats forecasts on back of Covid and shingles treatments

    UK drugmaker points to ‘good momentum’ as sales rise by a third in ‘landmark year’

  • Tuesday, 26 April, 2022
    Special ReportFT Health: Innovation in Healthcare
    Europe’s push to rival US biotech hubs faces hit from market slump

    Rout revives fears of American buyers swooping on the continent’s start-ups

  • Monday, 25 April, 2022
    Roche Holding AG
    Roche sales boosted by North American demand for Covid tests

    Swiss pharmaceuticals group expects revenue from coronavirus treatments will decline this year

  • Sunday, 24 April, 2022
    Venture capital investment
    Cambridge venture fund now runs $1bn of assets after record raising

    CIC likens innovation and entrepreneurship in UK university city to Silicon Valley

  • Wednesday, 20 April, 2022
    Coronavirus treatment
    Novavax publishes positive initial data for first combined Covid and flu vaccine

    Early clinical findings show that two-in-one shot could be safe and effective

  • Wednesday, 20 April, 2022
    GlaxoSmithKline PLC
    GSK workers vote to strike over below inflation pay rise

    Several hundred staff set stage for first walkout in drugmaker’s history

  • Wednesday, 20 April, 2022
    Oxford BioMedica PLC
    Oxford BioMedica warns revenue will be hit by AstraZeneca jab uncertainty

    Shares slide as London-listed group announces ‘pause’ in vaccine manufacturing

  • Wednesday, 20 April, 2022
    News in-depthChinese politics & policy
    Scientists urge China to replace its faltering Covid vaccines

    Omicron outbreak in Shanghai has refocused attention on waning efficacy of homegrown jabs

  • Tuesday, 19 April, 2022
    Covid-19 vaccines
    Moderna and Pfizer urged to share vaccine technology with developing world

    Proxy advisers back shareholder resolutions as new shot shows promising results

  • Tuesday, 19 April, 2022
    Disease control and prevention
    Cancer research under pressure as clinicians battle with Covid

    Staff shortages have hit many trials but spurred innovation within some companies

  • Tuesday, 19 April, 2022
    Pharmaceuticals sector
    Cambridge start-up searches for next Covid jab in animal faeces

    University spinout is developing two vaccines to help prevent future pandemics

  • Wednesday, 13 April, 2022
    GlaxoSmithKline PLC
    GSK to buy Sierra Oncology for £1.5bn to boost cancer drug pipeline

    Sierra’s bone marrow cancer treatment had positive clinical trial results in January

  • Monday, 4 April, 2022
    Novartis AG
    Novartis shakes up structure to strengthen US business

    Chief executive says changes will make Swiss drugmaker ‘more agile and competitive’

  • Wednesday, 23 March, 2022
    News in-depthCovid-19 vaccines
    Scientists debate fourth Covid vaccine dose as Omicron cases rise

    Experts accept need to inoculate elderly, but some are less convinced about revaccinating younger, healthy people

  • Monday, 21 March, 2022
    Health Care
    Blood testing start-up Osler to tap investors as it primes device launch

    Oxford university spinout seeks to add to $100mn already raised in drive to succeed where Theranos failed

  • Sunday, 20 March, 2022
    The Big Read
    Will AI turbocharge the hunt for new drugs?

    Advocates point to the pandemic as proof of its value in healthcare even as critics dismiss its use in drug discovery as ‘hype’

  • Friday, 18 March, 2022
    War in Ukraine
    Western drugmakers walk ethical tightrope over Russian ties

    Companies must balance needs of sick patients while also demonstrating opposition to war in Ukraine

  • Thursday, 17 March, 2022
    Covid-19 vaccines
    AstraZeneca prepared to ditch effort to secure US approval for Covid vaccine

    UK drugmaker’s R&D chief says abandoning market would have little impact

  • Sunday, 13 March, 2022
    News in-depthWar in Ukraine
    Aid efforts struggle to contain Ukraine’s multiple health crises

    Russia’s attacks on hospitals, shortages of drugs and a polio outbreak are causing a humanitarian disaster

Previous page You are on page 1 Next page

Be part of FT Community

Discover unmissable flagship events and members only communities to expand your thinking and elevate your career

FT LiveThe Global Boardroom: 5th EditionWhere next on the road to recovery?
Tuesday, 7th JuneDigital Conference
Learn more about FT Community

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT TransactSecondary Schools

Tools

PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

Community & Events

FT CommunityFT LiveFT ForumsFT Board DirectorBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2022. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

International Edition

Subscribe for full access
  • Switch to UK Edition
  • Top sections
  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
  • US
    • US Economy
    • US Companies
    • US Politics & Policy
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    • Cryptocurrencies
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • How to Spend It
  • Special Reports
  • FT recommends
  • Lex
  • Alphaville
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • FTfm
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Community
    • FT Live
    • FT Forums
    • Board Director Programme
  • myFT
  • Portfolio
  • Today's Newspaper (ePaper)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In